Previous Close | 2.4800 |
Open | 2.4500 |
Bid | 2.4100 x 900 |
Ask | 2.7100 x 1800 |
Day's Range | 2.4400 - 2.7100 |
52 Week Range | 2.1200 - 7.7500 |
Volume | |
Avg. Volume | 34,467 |
Market Cap | 77.151M |
Beta (5Y Monthly) | 1.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3510 |
Earnings Date | Mar 22, 2022 - Mar 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.50 |
LA JOLLA, Calif., May 17, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference.
LA JOLLA, Calif., May 12, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.
LA JOLLA, Calif., May 12, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association (EHA) has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease (aGVHD).